Get started
Author

Yuji Kojima

Observed name: Yuji KOJIMA
OpenAlex ID: A5112644274
Increased lipid peroxidation in patients with non‐alcoholic fatty liver disease and chronic hepatitis C as measured by the plasma level of 8‐isoprostane
2006 · Masayoshi Konishi, Motoh Iwasa, et al. · Journal of Gastroenterology and Hepatology · 82
Effect of lactoferrin in patients with chronic hepatitis C: Combination therapy with interferon and ribavirin
2007 · Masahiko Kaito, Motoh Iwasa, et al. · Journal of Gastroenterology and Hepatology · 71
Does interferon-free direct-acting antiviral therapy for hepatitis C after curative treatment for hepatocellular carcinoma lead to unexpected recurrences of HCC? A multicenter study by the Japanese Red Cross Hospital Liver Study Group
2018 · Toshie Mashiba, Kouji Joko, et al. · PLoS ONE · 57
PDF
The Real-World Data in Japanese Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib from a Nationwide Multicenter Study
2021 · Kaoru Tsuchiya, Masayuki Kurosaki, et al. · Cancers · 50
PDF
Detection of hepatitis C virus RNA by nested polymerase chain reaction in sera of patients with chronic non-A, non-B hepatitis treated with interferon
1992 · Yoshinao Kobayashi, Shozo Watanabe, et al. · Journal of Hepatology · 46
Change in Fibrosis 4 Index as Predictor of High Risk of Incident Hepatocellular Carcinoma After Eradication of Hepatitis C Virus
2020 · Nobuharu Tamaki, Masayuki Kurosaki, et al. · Clinical Infectious Diseases · 43
PDF
Real-world efficacy and safety of ledipasvir and sofosbuvir in patients with hepatitis C virus genotype 1 infection: a nationwide multicenter study by the Japanese Red Cross Liver Study Group
2018 · Keiji Tsuji, Masayuki Kurosaki, et al. · Journal of Gastroenterology · 43
Real‐world efficacy and safety of sofosbuvir + ribavirin for hepatitis C genotype 2: A nationwide multicenter study by the Japanese Red Cross Liver Study Group
2018 · Takehiro Akahane, Masayuki Kurosaki, et al. · Hepatology Research · 33
Real‐world clinical outcomes of sofosbuvir and velpatasvir treatment in HCV genotype 1‐ and 2‐infected patients with decompensated cirrhosis: A nationwide multicenter study by the Japanese Red Cross Liver Study Group
2021 · Toshifumi Tada, Masayuki Kurosaki, et al. · Journal of Medical Virology · 32
Validity of Japanese version of SARC‐F questionnaire in patients with chronic liver disease
2018 · Satoshi Ida, Yuji Kojima, et al. · Journal of Gastroenterology and Hepatology · 22
Detectable HBV DNA during nucleos(t)ide analogues stratifies predictive hepatocellular carcinoma risk score
2020 · Shun Kaneko, Masayuki Kurosaki, et al. · Scientific Reports · 18
PDF
Iron reduction therapy by phlebotomy reduces lipid peroxidation and oxidative stress in patients with chronic hepatitis C
2006 · Masahiko Kaito, Motoh Iwasa, et al. · Journal of Gastroenterology · 18
Hepatocellular Carcinoma Risk Assessment for Patients With Advanced Fibrosis After Eradication of Hepatitis C Virus
2021 · Nobuharu Tamaki, Masayuki Kurosaki, et al. · Hepatology Communications · 16
PDF
Decreased protein C activation in patients with fulminant hepatic failure
2006 · Michihiko Yamaguchi, Esteban C Gabazza, et al. · Scandinavian Journal of Gastroenterology · 16
Real-World Data on Ramucirumab Therapy including Patients Who Experienced Two or More Systemic Treatments: A Multicenter Study
2022 · Yutaka Yasui, Masayuki Kurosaki, et al. · Cancers · 12
PDF
Efficacy of daclatasvir plus asunaprevir in patients with hepatitis C virus infection undergoing and not undergoing hemodialysis
2018 · Hideki Fujii, Hiroyuki Kimura, et al. · Hepatology Research · 12
A validation study of after direct‐acting antivirals recommendation for surveillance score for the development of hepatocellular carcinoma in patients with hepatitis C virus infection who had received direct‐acting antiviral therapy and achieved sustained virological response
2021 · Toshifumi Tada, Masayuki Kurosaki, et al. · JGH Open · 11
PDF
Risk factors for hepatocellular carcinoma at baseline and 1 year after initiation of nucleos(t)ide analog therapy for chronic hepatitis B
2022 · Shun Kaneko, Masayuki Kurosaki, et al. · Journal of Medical Virology · 9
A 10-year Follow-up Study of a Japanese Family with Ferroportin Disease A: Mild Iron Overload with Mild Hyperferritinemia Co-occurring with Hyperhepcidinemia May Be Benign
2018 · Hisao Hayashi, Motoyoshi Yano, et al. · Internal Medicine · 7
PDF
Changing clinical and molecular characteristics of hepatitis E virus infection in Mie Prefecture, Japan: Disappearance of indigenous subtype 3e strains
2019 · Tatsunori Nakano, Hiroshi Okano, et al. · Hepatology Research · 6
The efficacy and safety of lenvatinib in patients who did not meet the inclusion criteria of the phase 3 trial (REFLECT trial) in real-world practice in Japan: A nationwide multicenter study in Japan.
2019 · Kaoru Tsuchiya, Masayuki Kurosaki, et al. · Journal of Clinical Oncology · 5
Efficacy of hepatitis C virus eradication after curative treatment for hepatocellular carcinoma in patients with advanced hepatocellular carcinoma and decreased hepatic functional reserve: A nationwide, multicentre study by the Japanese Red Cross Liver Study Group
2022 · Toshie Mashiba, Kouji Joko, et al. · Journal of Viral Hepatitis · 4
General evaluation score for predicting the development of hepatocellular carcinoma in patients with advanced liver fibrosis associated with hepatitis C virus genotype 1 or 2 after direct‐acting antiviral therapy
2022 · Toshifumi Tada, Masayuki Kurosaki, et al. · JGH Open · 3
Safety and efficacy of immune checkpoint inhibitors (ICIs) in patients (pts) with cardiac metastases (mets) from solid tumors.
2023 · Amin Nassar, Sarah Abou Alaiwi, et al. · Journal of Clinical Oncology · 2
PDF
Real‐world long‐term analysis of daclatasvir plus asunaprevir in patients with hepatitis C virus infection
2022 · Hideki Fujii, Hiroyuki Kimura, et al. · JGH Open · 2
PDF
Works count: 31
Citation count: 623
H-index: 14
I10-index: 17
Year
Topic
Type